Mineralys Therapeutics Common Stock Performance
| MLYS Stock | 27.60 0.26 0.93% |
The company secures a Beta (Market Risk) of 1.59, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mineralys Therapeutics will likely underperform. At this point, Mineralys Therapeutics has a negative expected return of -0.72%. Please make sure to verify Mineralys Therapeutics' information ratio and kurtosis , to decide if Mineralys Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Mineralys Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (6.45) | Five Day Return (3.86) | Year To Date Return (21.98) | Ten Year Return 51.08 | All Time Return 51.08 |
1 | Disposition of 1000000 shares by Slingsby Brian Taylor of Mineralys Therapeutics, at 43.35 subject to Rule 16b-3 | 11/20/2025 |
2 | How Investors May Respond To Mineralys Therapeutics After 287.5 Million Upsized Capital Raise and New Institutional Backing | 12/01/2025 |
3 | Mineralys Therapeutics Stock Price Down 3.4 percent Whats Next | 12/30/2025 |
4 | Disposition of 3629 shares by Rodman David Malcom of Mineralys Therapeutics at 15.44 subject to Rule 16b-3 | 01/02/2026 |
5 | Disposition of 10121 shares by Rodman David Malcom of Mineralys Therapeutics at 15.44 subject to Rule 16b-3 | 01/05/2026 |
6 | Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 | 01/06/2026 |
7 | Mineralys Therapeutics, Inc. MLYS Shares Acquired by Hennion Walsh Asset Management Inc. | 01/09/2026 |
8 | Disposition of 6348 shares by Rodman David Malcom of Mineralys Therapeutics at 1.08 subject to Rule 16b-3 | 01/12/2026 |
9 | Disposition of 11367 shares by Rodman David Malcom of Mineralys Therapeutics at 32.6071 subject to Rule 16b-3 | 01/14/2026 |
10 | Disposition of 416 shares by Rodman David Malcom of Mineralys Therapeutics at 15.44 subject to Rule 16b-3 | 01/20/2026 |
11 | Mineralys Therapeutics Files Lorundrostat NDA Following Positive Clinical Milestones | 01/30/2026 |
12 | Traders Purchase Large Volume of Mineralys Therapeutics Put Options | 02/06/2026 |
13 | Disposition of 2171 shares by Rodman David Malcom of Mineralys Therapeutics at 16.0 subject to Rule 16b-3 | 02/09/2026 |
14 | Assessing Mineralys Therapeutics Valuation After Recent Share Price Weakness And Strong 1 Year Return | 02/12/2026 |
| Begin Period Cash Flow | 49.3 M | |
| Total Cashflows From Investing Activities | 115 M | |
| Free Cash Flow | -166.4 M |
Mineralys | Build AI portfolio with Mineralys Stock |
Mineralys Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,426 in Mineralys Therapeutics Common on November 15, 2025 and sell it today you would lose (1,640) from holding Mineralys Therapeutics Common or give up 37.05% of portfolio value over 90 days. Mineralys Therapeutics Common is currently does not generate positive expected returns and assumes 3.0649% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Mineralys, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mineralys Therapeutics Target Price Odds to finish over Current Price
The tendency of Mineralys Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 27.60 | 90 days | 27.60 | about 97.0 |
Based on a normal probability distribution, the odds of Mineralys Therapeutics to move above the current price in 90 days from now is about 97.0 (This Mineralys Therapeutics Common probability density function shows the probability of Mineralys Stock to fall within a particular range of prices over 90 days) .
Mineralys Therapeutics Price Density |
| Price |
Predictive Modules for Mineralys Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mineralys Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mineralys Therapeutics is not an exception. The market had few large corrections towards the Mineralys Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mineralys Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mineralys Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.51 | |
β | Beta against Dow Jones | 1.59 | |
σ | Overall volatility | 4.67 | |
Ir | Information ratio | -0.12 |
Mineralys Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mineralys Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mineralys Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mineralys Therapeutics generated a negative expected return over the last 90 days | |
| Mineralys Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (177.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mineralys Therapeutics generates negative cash flow from operations | |
| Mineralys Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing Mineralys Therapeutics Valuation After Recent Share Price Weakness And Strong 1 Year Return |
Mineralys Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mineralys Stock often depends not only on the future outlook of the current and potential Mineralys Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mineralys Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.5 M | |
| Cash And Short Term Investments | 198.2 M |
Mineralys Therapeutics Fundamentals Growth
Mineralys Stock prices reflect investors' perceptions of the future prospects and financial health of Mineralys Therapeutics, and Mineralys Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mineralys Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 79.14 M | ||||
| Price To Book | 4.27 X | ||||
| EBITDA | (192.36 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 7.30 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Earnings Per Share | (2.92) X | ||||
| Market Capitalization | 2.36 B | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
About Mineralys Therapeutics Performance
Assessing Mineralys Therapeutics' fundamental ratios provides investors with valuable insights into Mineralys Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mineralys Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (1.16) | (1.21) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.07) | (1.02) |
Things to note about Mineralys Therapeutics performance evaluation
Checking the ongoing alerts about Mineralys Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mineralys Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mineralys Therapeutics generated a negative expected return over the last 90 days | |
| Mineralys Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (177.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mineralys Therapeutics generates negative cash flow from operations | |
| Mineralys Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Assessing Mineralys Therapeutics Valuation After Recent Share Price Weakness And Strong 1 Year Return |
- Analyzing Mineralys Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mineralys Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mineralys Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mineralys Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mineralys Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mineralys Therapeutics' stock. These opinions can provide insight into Mineralys Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.